


PRESS RELEASE

Metropolis Healthcare delivers Strong Q1FY26 Performance with 23% Revenue Growth to INR 386 Crore; PAT Up 19% YoY

Mumbai, India, 7th August 2025: Ameera Shah-led Metropolis Healthcare Limited (**NSE: METROPOLIS |BSE: 542650**), India’s second-largest and most respected pathology laboratory chain, today announced its unaudited consolidated financial results for the quarter ended June 30, 2025.



Key Financial & Operational Highlights – Q1FY26

- **Patient and Test Volumes grew by 11% and 12% YoY**, respectively, with **B2C & B2B revenues rising 19% and 29% YoY**.
- **Revenue per Patient (RPP) and Revenue per Test (RPT) increased by 11% and 10% YoY**, driven by a richer test mix, scientific upselling, and adoption of the recommendation engine.
- **Specialty Diagnostics recorded the highest revenue growth at 32%**, led by strong traction in Oncology, Genomics, NGS, and Women & Child Health, supported by scientific engagement, AI adoption, and innovation-led differentiation.
- **TruHealth wellness & illness bundled portfolio grew by 24%**, driven by premium packages with home-based ECG, vital checks, and consultations, reflecting growing consumer demand for preventive, end-to-end care.
- **Our geographic footprint continued to expand, with North India’s revenue contribution rising to 17% from 8%, and Tier III cities alone registering a revenue growth of 17%**.
- The acquisitions have been successfully integrated both financially and operationally, and remain on track as per plan.

“Rising health awareness is fuelling demand for advanced diagnostics across prevention, wellness, and complex illness detection. These trends are expanding the formal diagnostics market and creating a broader revenue opportunities across industry players. Encouragingly, the market is stabilizing, with reduced pricing pressures and a stronger focus on clinical quality and trust.

At Metropolis, we continue to focus on high-value and complex testing, where accuracy, scientific excellence, and deep domain expertise are critical. Our recent acquisitions have strengthened our presence in specialised diagnostics, opening up premium growth opportunities and enhancing revenue quality. With sustained investments in Specialty Diagnostics, Genomics, and our Centers of Excellence, we are building a differentiated and future-ready healthcare enterprise that is well-positioned for long-term value creation.”

~ Ameera Shah, Promoter and Executive Chairperson, Metropolis Healthcare Limited.

“We’ve begun FY26 on a strong footing, delivering 23% growth in overall revenue and a 19% increase in PAT. This growth has been driven by healthy organic momentum in our core business, supported by rising patient volumes, a stronger test mix, and improved realizations.

Our disciplined execution, strong cost management, and sharper commercial focus are yielding tangible results. With a comprehensive test menu and a pan-India network, we are now seeing operational efficiencies driven by our own automation and process improvements. As we move forward, our priority remains consistent execution—enhancing service quality, scaling operations effectively, and delivering sustainable, profitable growth.”

~ Surendran Chemmenkotil, Managing Director, Metropolis Healthcare Limited.

About Metropolis Healthcare Limited: Established in 1981, Metropolis Healthcare Limited is India’s second-largest diagnostic chain, led by visionary leader Ms. Ameera Shah. With over four decades of excellence, Metropolis has been a pioneer in delivering best-in-class diagnostic services to patients, healthcare providers, and corporates across India and Africa. The company’s extensive footprint spans 28 states, 7 Union Territories, and over 750+ towns in India, supported by a robust network of more than 222 laboratories, ~ 4,500 patient service centers, and over 10,000 touchpoints. Each year, Metropolis serves millions of individuals by providing actionable health insights that empower better clinical outcomes. Metropolis offers a comprehensive range of more than 4,100 tests and profiles, including advanced tests for diagnosing cancer, neurological disorders, infectious diseases, and various genetic abnormalities. The company’s commitment to quality and accuracy is reinforced by its consistent CAP proficiency score of over 99% for the past decade, placing it among the top 1% of laboratories worldwide for quality assurance. The Metropolis philosophy is built on the pillars of technological superiority, a warm, patient-centric approach, and reliable diagnostic reports. For more information, please visit www.metropolisindia.com or click on [Twitter](#), [Facebook](#), or [LinkedIn](#)

Safe harbor statement: Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For further details please contact:

<p>Company: Metropolis Healthcare Ltd. CIN -L73100MH2000PLC192798 Mr. Jeyasingh Balakrishnan Head - Corporate Communications jeyasingh.b@metropolisindia.com</p>	<p>Investor Relations Advisors: Strategic Growth Advisors Pvt. Ltd. CIN: U74140MH2010PTC204285 Mr. Shogun Jain / Mr. Sagar Shroff +91 77383 77756 / +91 98205 19303 shogun.jain@sgapl.net / sagar.shroff@sgapl.net</p>
--	--